Zhang X., Yeung D.C., Karpisek M., et al
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (surpass-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 surpass-3 trial
Animal reproduction studies, required for FDA approval, have shown some findings that warrant consideration
In SURPASS-2 , all three tirzepatide doses delivered superior A1C and body weight reductions from baseline compared to semaglutide
Nonetheless, Biogen plans to move it into Phase 3 testing because of signals suggesting the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose